Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

Compare

6,357 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VRTX Analyst Ratings

Moderate Buy

14 Buy

11 Hold

0 Sell

Based on 25 analysts giving stock ratings to

Vertex

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VRTX Stock 12 Month Forecast

Average Price Target

$488.00

▲(23.19% Upside)

Based on 25 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $488.00 with a high forecast of $624.00 and a low forecast of $401.00. The average price target represents a 23.19% change from the last price of $396.12.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"400":"$400","625":"$625","456.25":"$456.3","512.5":"$512.5","568.75":"$568.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":624,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$624.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":488,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$488.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":401,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$401.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[400,456.25,512.5,568.75,625],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401,418.15384615384613,435.3076923076923,452.46153846153845,469.61538461538464,486.7692307692308,503.9230769230769,521.0769230769231,538.2307692307693,555.3846153846154,572.5384615384615,589.6923076923076,606.8461538461538,{"y":624,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401,407.6923076923077,414.38461538461536,421.0769230769231,427.7692307692308,434.46153846153845,441.15384615384613,447.84615384615387,454.53846153846155,461.2307692307692,467.9230769230769,474.61538461538464,481.3076923076923,{"y":488,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401,401,401,401,401,401,401,401,401,401,401,401,401,{"y":401,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":495.89,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":469.76,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":471.12,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":465.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":402.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":461.68,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":479.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":484.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":498.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.43,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":452.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":462.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$624.00

Average Price Target$488.00

Lowest Price Target$401.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Evan Seigerman

BMO Capital

$530

Buy

33.80%

Upside

Reiterated

09/05/25

Vertex Pharmaceuticals: Promising Growth and Strategic Positioning Justify Buy Rating

Christopher Raymond

Raymond James

$401

Hold

1.23%

Upside

Initiated

09/02/25

Vertex Pharmaceuticals initiated with a Market Perform at Raymond JamesVertex Pharmaceuticals initiated with a Market Perform at Raymond James

Cory Kasimov

Evercore ISI

$515.16→$510

Buy

28.75%

Upside

Initiated

08/22/25

Analysts Offer Insights on Healthcare Companies: Brainsway (NASDAQ: BWAY) and Vertex Pharmaceuticals (NASDAQ: VRTX)

William Pickering

Bernstein

―

Hold

―

Reiterated

08/22/25

Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)

Salveen Richter

Goldman Sachs

$624

Buy

57.53%

Upside

Reiterated

08/11/25

Goldman Sachs Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

Whitney Ijem

Canaccord Genuity

$424→$411

Hold

3.76%

Upside

Reiterated

08/06/25

Vertex Pharmaceuticals price target lowered to $411 from $424 at CanaccordVertex Pharmaceuticals price target lowered to $411 from $424 at Canaccord

Debjit Chattopadhyay

Guggenheim

$558→$546

Buy

37.84%

Upside

Reiterated

08/06/25

Guggenheim Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

David Risinger

Leerink Partners

$503→$458

Hold

15.62%

Upside

Reiterated

08/06/25

Vertex Pharmaceuticals: Hold Rating Amid Mixed Q2 Results and Pain Management Setbacks

Mohit Bansal

Wells Fargo

$460

Buy

16.13%

Upside

Upgraded

08/06/25

Vertex Pharmaceuticals: Buy Rating Upgraded to Overweight Amid Promising Pipeline and Strong Financial Position

Geoff Meacham

Citi

$575→$550

Buy

38.85%

Upside

Reiterated

08/06/25

Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Joon Lee

Truist Financial

$520→$490

Buy

23.70%

Upside

Reiterated

08/05/25

Truist Financial Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Myles Minter

William Blair

―

Buy

―

Reiterated

08/05/25

Vertex Pharmaceuticals: Strong Financial Performance and Promising Pipeline Justify Buy Rating

Andrew Fein

H.C. Wainwright

$550→$478

Buy

20.67%

Upside

Reiterated

08/05/25

Vertex price target lowered to $478 from $550 at H.C. WainwrightVertex price target lowered to $478 from $550 at H.C. Wainwright

Joseph Stringer

Needham

―

Hold

―

Reiterated

08/05/25

Vertex Pharmaceuticals: Strong Financials Overshadowed by Challenges in Pain Program Leading to Hold Rating

Greg Harrison

Scotiabank

$442→$438

Hold

10.57%

Upside

Reiterated

08/05/25

Scotiabank Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Evan Seigerman

BMO Capital

$530

Buy

33.80%

Upside

Reiterated

09/05/25

Vertex Pharmaceuticals: Promising Growth and Strategic Positioning Justify Buy Rating

Christopher Raymond

Raymond James

$401

Hold

1.23%

Upside

Initiated

09/02/25

Vertex Pharmaceuticals initiated with a Market Perform at Raymond JamesVertex Pharmaceuticals initiated with a Market Perform at Raymond James

Cory Kasimov

Evercore ISI

$515.16→$510

Buy

28.75%

Upside

Initiated

08/22/25

Analysts Offer Insights on Healthcare Companies: Brainsway (NASDAQ: BWAY) and Vertex Pharmaceuticals (NASDAQ: VRTX)

William Pickering

Bernstein

―

Hold

―

Reiterated

08/22/25

Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)

Salveen Richter

Goldman Sachs

$624

Buy

57.53%

Upside

Reiterated

08/11/25

Goldman Sachs Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

Whitney Ijem

Canaccord Genuity

$424→$411

Hold

3.76%

Upside

Reiterated

08/06/25

Vertex Pharmaceuticals price target lowered to $411 from $424 at CanaccordVertex Pharmaceuticals price target lowered to $411 from $424 at Canaccord

Debjit Chattopadhyay

Guggenheim

$558→$546

Buy

37.84%

Upside

Reiterated

08/06/25

Guggenheim Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

David Risinger

Leerink Partners

$503→$458

Hold

15.62%

Upside

Reiterated

08/06/25

Vertex Pharmaceuticals: Hold Rating Amid Mixed Q2 Results and Pain Management Setbacks

Mohit Bansal

Wells Fargo

$460

Buy

16.13%

Upside

Upgraded

08/06/25

Vertex Pharmaceuticals: Buy Rating Upgraded to Overweight Amid Promising Pipeline and Strong Financial Position

Geoff Meacham

Citi

$575→$550

Buy

38.85%

Upside

Reiterated

08/06/25

Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Joon Lee

Truist Financial

$520→$490

Buy

23.70%

Upside

Reiterated

08/05/25

Truist Financial Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Myles Minter

William Blair

―

Buy

―

Reiterated

08/05/25

Vertex Pharmaceuticals: Strong Financial Performance and Promising Pipeline Justify Buy Rating

Andrew Fein

H.C. Wainwright

$550→$478

Buy

20.67%

Upside

Reiterated

08/05/25

Vertex price target lowered to $478 from $550 at H.C. WainwrightVertex price target lowered to $478 from $550 at H.C. Wainwright

Joseph Stringer

Needham

―

Hold

―

Reiterated

08/05/25

Vertex Pharmaceuticals: Strong Financials Overshadowed by Challenges in Pain Program Leading to Hold Rating

Greg Harrison

Scotiabank

$442→$438

Hold

10.57%

Upside

Reiterated

08/05/25

Scotiabank Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

1 Month

xxx

Success Rate

25/31 ratings generated profit

Average Return

+4.50%

initiated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.65% of your transactions generating a profit, with an average return of +4.50% per trade.

3 Months

xxx

Success Rate

19/27 ratings generated profit

Average Return

+6.76%

upgraded a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.37% of your transactions generating a profit, with an average return of +6.76% per trade.

1 Year

Cory KasimovEvercore ISI

Success Rate

23/31 ratings generated profit

Average Return

+20.79%

initiated a buy rating 18 days ago

Copying Cory Kasimov's trades and holding each position for 1 Year would result in 74.19% of your transactions generating a profit, with an average return of +20.79% per trade.

2 Years

xxx

Success Rate

26/31 ratings generated profit

Average Return

+24.78%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 83.87% of your transactions generating a profit, with an average return of +24.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRTX Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VRTX has received 26 Buy Ratings, 24 Hold Ratings, and 0 Sell Ratings. VRTX average Analyst price target in the past 3 months is 488.00.

Each month's total comprises the sum of three months' worth of ratings.

VRTX Financial Forecast

VRTX Earnings Forecast

Next quarter’s earnings estimate for VRTX is $4.61 with a range of $4.33 to $5.01. The previous quarter’s EPS was $4.52. VRTX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year VRTX has Preformed in-line its overall industry.

VRTX Sales Forecast

Next quarter’s sales forecast for VRTX is $3.05B with a range of $2.94B to $3.14B. The previous quarter’s sales results were $2.99B. VRTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.26% of the time in the same period. In the last calendar year VRTX has Preformed in-line its overall industry.

VRTX Stock Forecast FAQ

What is VRTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 488.00.

What is VRTX’s upside potential, based on the analysts’ average price target?

Vertex Pharmaceuticals has 23.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VRTX a Buy, Sell or Hold?

Vertex Pharmaceuticals has a consensus rating of Moderate Buy which is based on 14 buy ratings, 11 hold ratings and 0 sell ratings.

What is Vertex Pharmaceuticals’s price target?

The average price target for Vertex Pharmaceuticals is 488.00. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $624.00 ,the lowest forecast is $401.00. The average price target represents 23.19% Increase from the current price of $396.12.

What do analysts say about Vertex Pharmaceuticals?

Vertex Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 25 Wall Streets Analysts.

How can I buy shares of VRTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

VRTX Analyst Ratings

VRTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vertex Pharmaceuticals

VRTX Analyst Recommendation Trends

VRTX Financial Forecast

VRTX Earnings Forecast

VRTX Sales Forecast

VRTX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts